
Models for Financing Antibiotic Development to Address Antimicrobial Resistance

Milken Institute statement on ARPA-H inclusion in FY2022 spending bill

Comments on FDA’s Draft Guidance for Industry, Investigators, and Other Stakeholders on Decentralized Clinical Trials for Drugs, Biological Products, and Devices - Docket ID FDA-2022-D-2870

Medicare Drug Price Negotiation Program comment letter
